Research at the UK DRI at UCL covers the journey from the person living with dementia to the laboratory and back again - with improved diagnosis and potential therapies put to the test.
From lab bench to bedside, and back again
UCL was selected as the hub of the UK DRI in 2016 because of its strength to bring together excellent clinical and basic neuroscience research to advance our understanding of neurodegeneration and identify novel targets and therapeutic approaches for dementia. As the hub, it has a larger research programme and also is the location for the national headquarters team who connect the whole institute together.
Research at the UK DRI at UCL covers the journey from the person living with dementia to the laboratory and back again - with improved diagnosis and potential therapies put to the test. The groups believe in intervening earlier in disease in order to change the trajectory.
We need to better understand the diversity and complexity of neurodegenerative diseases, like Alzheimer's disease, in order to understand the mechanisms involved, and ultimately how we can alter them to improve people's lives.
We must find treatments quicker, and that's why the UK DRI at UCL is taking a novel approach by integrating diverse expertise for efficiency, from genetics to diagnostics.
This work is enhanced by incredible clinical resources. Researchers have access to unique clinical cohorts, where comprehensive data has been collected throughout disease progression including memory assessments and brain tissue. The UK DRI at UCL provides a clinical arm to the whole of the UK DRI.
The future iconic home of the UK DRI at UCL will be alongside UCL's Queen Square Institute of Neurology in a new building on Gray's Inn Road.
Visit the UK DRI at UCL local website for up-to-date news.
Applications are invited for a Research Fellow to join the Schiavo Lab at the UK DRI at UCL for the project: Neurobiology of synaptic tau and its propagation in Alzheimer’s disease. In Alzheimer’s disease (AD), pathological conformations of the microtubule-associate protein tau spread in the brain via neuronal connections, likely to be synaptic. However, the mechanism of tau release from synapses has not yet been characterised. Understanding how pathological tau reaches the synapse, accumulates in vesicles, is released, and eventually is taken up by postsynaptic cells, is a hot topic in AD research. We believe that by identifying the molecular mechanisms controlling tau release and spreading, we could revolutionise the treatment of AD. The findings are likely to be relevant also for other human brain disorders characterised by protein aggregation and spreading. Ref: 1881579, Closing date: 7 Feb 2022Apply to centre
The UK DRI runs a Cross-Centre Postdoctoral Programme, designed to simultaneously fund exciting emerging science and to foster intra-UK DRI collaboration through support of a postdoctoral position based across two UK DRI Centres. This is an exciting opportunity to work on a research project to establish a synergistic collaboration between Prof David Sharp’s laboratory (based at the UK DRI Care Research & Technology Centre) and Dr Marc Aurel Busche’s laboratory (based at the UK DRI at UCL). You’ll examine the effects of traumatic brain injury on neuronal circuit and neurovascular function in vivo, recording neuronal activity and vascular dynamics using state of the art two-photon and electrophysiological (Neuropixels) methods and linking this to available human datasets. This is fantastic chance to work independently on a high impact, state-of-the-art collaborative and cross-species project in a stimulating and vibrant research environment. Ref: 1881887, Closing date: 14 February 2022Apply to centre